


Alloy Therapeutics enters Japanese market by establishing operations at Shonan Health Innovation Park

23 May 2025 | News

With launch of its first cell therapy base in Japan



Alloy Therapeutics Inc., a US-based biotechnology ecosystem company, has recently opened its first location in Japan – at Shonan iPark in Kanagawa, one of the world's most advanced research facilities, where it is establishing a cell therapy base.

To support its expansion into Japan, Alloy has formed Alloy Therapeutics Co., Ltd. and appointed Yoshihide Ishii (Victor Stone) as Chief Executive Officer of its Japanese subsidiary.

Building on collaboration with Takeda announced in November 2024, Alloy will advance cell therapy leveraging its proprietary iCAR-T technology. Originating with the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was developed through the T-CiRA program, led by Professor Shin Kaneko of Kyoto University's Center for iPS Cell Research and Application (CiRA) in collaboration with Takeda.

The iCAR-T platform is noteworthy for being the first iPS CAR-T technology to consistently deliver superior potency over autologous CAR-T in animal studies, and enabling 'off-the-shelf' product profiles that significantly lower costs and increase access. Now, Alloy offers democratised access to this powerful cell therapy engine, combining best-in-class science with a fully integrated, scalable drug development platform.